查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593757

動物疫苗市場：依產品、動物類型、給藥途徑、通路、地區、機會、預測，2017-2031

Animal Vaccines Market Assessment, By Product, By Animal Type, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 224 Pages | 商品交期: 3-5個工作天內

價格
全球動物疫苗市場規模預計將從 2023 年的 90.3 億美元成長到 2031 年的 138 億美元，2024-2031 年預測期間複合年增長率為 5.44%。由於動物疾病的流行以及投資者和市場參與者的興趣日益濃厚，預計在預測期內，動物疫苗的市場需求將呈指數級增長。

動物和人類透過各種重要因素連結在一起。沒有動物就很難生存，但另一方面，動物也面臨因致病物質等各種內外因素而引發多種疾病的風險。動物疫苗市場是專注於牲畜和伴侶動物疾病預防的獸藥業務的重要組成部分。動物疾病發病率的增加、全球對動物性蛋白質需求的增加以及疫苗技術的進步導致對動物疫苗的強勁需求。

根據世界衛生組織（WHO）的數據，60%的已知人類傳染病可以透過動物傳播，75%的人類新興傳染病可以透過動物傳播。疫苗主要有四種：減毒活疫苗、滅活疫苗、次單位疫苗和新興DNA疫苗，適用於牛、豬、雞等家畜動物、狗、貓等伴侶動物。

本報告調查了全球獸用疫苗市場，包括市場概述、產品趨勢、動物類型、給藥途徑、分銷管道、區域趨勢以及進入市場的公司概況。

目錄

第1章專案範圍與定義

第2章研究方法

第 3 章執行摘要

第4章2017-2031年全球動物疫苗市場展望

  • 市場規模分析與預測
  • 市佔率分析與預測
  • 2023 年市場地圖分析
    • 按產品
    • 依動物類型
    • 依給藥途徑
    • 按分銷管道
    • 按地區

第5章北美動物疫苗市場展望，2017-2031

第 6 章歐洲動物疫苗市場展望，2017-2031

第 7 章亞太動物疫苗市場展望，2017-2031

第8章2017-2031年南美洲獸用疫苗市場前景

第9章2017-2031年中東及非洲獸用疫苗市場前景

第10章供需分析

第11章進出口分析

第12章價值鏈分析

第 13 章波特五力分析

第14章PESTLE分析

第15章價格分析

第 16 章市場動態

第17章市場趨勢與發展

第 18 章監理架構與創新

第19章專利狀況

第 20 章個案研究

第21章競爭態勢

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名進入公司的 SWOT 分析
  • 市場前10位主要參與者的情況
    • Merck & Co, Inc.
    • Neogen Corporation
    • Biogenesis Bago
    • Vira Vaccine Shaya
    • Biovac Ltd
    • Zoetis Services, LLC
    • Medvet Pharma Pvt, Ltd
    • Grand Pharma Co, Ltd
    • LABORATORIOS CALIER, S.A.

第 22 章策略建議

第23章查詢及免責聲明

Product Code: MX12269

Global animal vaccines market is projected to witness a CAGR of 5.44% during the forecast period 2024-2031, growing from USD 9.03 billion in 2023 to USD 13.80 billion in 2031. The market demand for animal vaccines is anticipated to thrive drastically in the forecast years due to the increasing prevalence of animal disease and the growing interest of investors and market players.

Animals and humans are linked and bonded together because of various critical factors. Life is difficult without animals, but at the time, due to various internal and external factors such as disease-causing agents, animals are confronted with many disease-causing risks. The animal vaccine market represents an important segment of the veterinary business, focusing on the prevention of diseases in livestock and companion animals. Increasing animal disease incidence, growing global demand for animal protein, and advancing vaccine technology contribute to a strong demand for animal vaccines. According to the WorldHealth Organization (WHO), 60% of the known infectious diseases in humans can be transmitted by animals, and 75% of emerging infections in humans are transmitted from animals. The four main types of vaccines are live attenuated, inactivated, subunit, and emerging DNA vaccines, which apply to livestock-farming animals, including cattle, pigs, and poultry, and companion animals, like dogs and cats. For instance, in January 2024, Ceva Sante Animale announced the strategic acquisition of Scout Bio, a pioneering biotech committed to advanced therapies in companion animals. This represents a major innovation step forward for Ceva in unlocking access to critical advances - including a pipeline of monoclonal antibodies and other gene therapy developments designed to treat chronic diseases in pets.

Increased Prevalence of Animal Diseases to Support the Growth of Animal Vaccines Market

Increasing animal disease prevalence is likely a significant growth driver for the global animal vaccines market. As the incidence of infectious and zoonotic diseases rises, the demand for effective preventive measures becomes more imperative. Avian influenza, foot-and-mouth disease, and canine distemper outbreaks present some of the most pressing and potent threats to animal health, food security, and public health. Since these diseases easily spread within and between populations, vaccination increasingly becomes a major strategy for mitigating risks and safeguarding livestock and companion animals. Increasing awareness of these diseases' economic and health implications incentivizes investment in vaccine development and distribution, therefore emphasizing the need for vaccination for healthy animal populations and sustainable agricultural practice. A growing incidence of animal diseases directly correlates with a strong demand for new, more effective vaccines, thereby causing rapid market growth. For instance, in February 2024, Penn Vet announced the launch of an mRNA research program to accelerate the development of veterinary mRNA-based vaccines and host-directed therapies targeting a diverse range of veterinary species. From avian influenza in poultry to viral infections in swine, the potential applications of mRNA-based vaccines are diverse. While mRNA vaccines are effective at producing antibody responses, they are not as effective at stimulating long-term lung, gut, and skin T cells necessary for barrier immunity in the majority of pathogens.

Advancements in Vaccines Technology to Increase Animal Vaccines Market Growth

Advancements in vaccine technology are a significant growth driver for the global animal vaccines market as they provide more effective and safer vaccination options. New technologies, including mRNA vaccines, subunit vaccines, and novel adjuvants, enhance immune responses and reduce adverse effects. Furthermore, these technologies facilitate the quick development of vaccines in response to emerging diseases or health threats within the animal population. New delivery methods, such as intranasal and oral vaccines, make the vaccines more convenient and compliant for veterinarians and pet owners to protect their animals. Continued investment in research and development ensures a pipeline of new and improved vaccines and expands treatment options for many species. In fact, with the growing demand for advanced, reliable, and efficient vaccines, these technological advancements have become important with regard to market growth and animal health and welfare. The increase in public knowledge regarding infertility and the availability of treatment options has reflected greater acceptance of assisted reproductive technologies. The more people have come to realize their possibilities through IVF, the more the number of people seeking these services continues to rise. Advances in technology, including better techniques for embryo culture, preimplantation genetic testing, and improvements in cryopreservation, have greatly increased the success rates of IVF treatment. This also makes the procedures more effective and can increase the number of options available to a patient, including the option of genetic screening and the possibility of freezing eggs or embryos for future use. Fertility clinics increasingly embrace high-tech facilities to attract and retain patients and further foster market growth. With continued spreading awareness and advancements in technology, the IVF market will expand steadily in the years to come.

For instance, on December 7, 2023, the U.S. Food and Drug Administration FDA cleared the kit for use by consumers. Mosie Inc. manufactured the first over-the-counter artificial insemination kit. The approval of the artificial insemination kit is expected to drive the market by making fertility treatments more accessible, affordable, and inclusive. For instance, in July 2023, Kansas State University's College of Veterinary Medicine announced the launch of a new Center on Vaccine Evaluation and Alternatives for Antimicrobials, or CVEAA, which focuses on developing animal vaccines and their usage. In addition to research projects supported by the U.S. Department of Agriculture and the Department of Homeland Security on safety and efficacy testing of experimental vaccines on African swine fever, classical swine fever, and porcine reproductive and respiratory syndrome, as well as co-development of new adjuvants for animal vaccines.

Attenuated Live Vaccines Segment to Dominate the Animal Vaccines Market

One of the major growth drivers of this market is the need for attenuated live vaccines because these vaccines create strong and long-lasting immunity. Attenuated live vaccines contain live, weakened pathogens and have been found to be highly effective in preventing a whole range of infectious diseases in livestock as well as companion animals. As they provide important benefits in terms of herd immunity and reduce disease outbreaks, attenuated live vaccines have become the first choice of many vaccination programs. Cost-effective and likely requiring fewer doses than inactivated vaccines, these vaccines are also much more attractive. Improved production technologies of vaccines further enhance the safety and efficacy of such products and dissolve the present controversy in terms of reversion to virulence. With growing awareness and acceptance of live vaccines and the associated benefits in terms of their application, the animal vaccine sector is likely to grow in the future. For instance, in August 2024, Hyderabad-based vaccine maker Indian Immunologicals Limited (IIL) developed a live-attenuated needle-free intra-nasal booster vaccine against the Sars-CoV-2 virus that causes Covid-19. The vaccine has been developed in partnership with Griffith University, Australia.

North America Dominates the Animal Vaccines Market

North America is anticipated to dominate the animal vaccines market owing to several factors, such as the high prevalence rate of animal diseases in the region. Chronic waste disease (CWD) has been identified in free-ranging cervids of 24 states and 4 provinces, as well as in captive cervid facilities of 19 states and three provinces. The latest finding was reported by the California Department of Fish and Wildlife, which states that CWD has been found in deer and elk This high prevalence drives the demand for effective animal vaccines. The United States and Canada are among the leaders, with larger organizations investing in research and development and coming up with innovative vaccination solutions. This region has a high demand for vaccines due to the importance of the livestock industry and the growing pet population, hence the awareness of preventative healthcare. Moreover, government measures are very strong in controlling animal diseases, which supports market growth. As North America continues to prioritize animal health, its dominant position in the global animal vaccines market is expected to persist, leading to ongoing advancements in vaccine technology and improved animal welfare outcomes.

For instance, in May 2024, MSD Animal Health, a business of Merck & Co., Inc., Rahway, N.J., USA, announced that the European Commission had granted marketing authorization for the Innovax-ND-H5 vaccine for chickens. The Innovax-ND-H5 vaccine is the first centrally registered vaccine in the European Union against the currently circulating avian influenza virus strains of clade 2.3.4.4b.

Future Market Scenario (2024-2031F)

The animal vaccines market has a potential and promising future market scenario with the dawn of numerous new trends and innovations. With growing awareness of animal health and welfare, effective vaccination solutions are sought by both the livestock and companion animal sectors. Advanced technologies like mRNA vaccines and vector-based vaccines are likely to improve the efficacy and safety of vaccinations, resulting in new ways of disease prevention. A "One Health" approach is increasingly encouraged to recognize the important interconnection between human, animal, and environmental health. This will also spur further investment in the research of zoonotic diseases and their vaccine development. The animal vaccines market is going to see tremendous growth in securing healthier populations around the world while new markets are opened by expanding markets in developing regions and progress in production and delivery methods.

For instance, in May 2024, HIPRA launched the new DIVENCE range, with innovative vaccines designed to intensively increase the prevention of the most viral diseases in cattle. DIVENCE represents the highest standards in terms of safety and efficacy against the most relevant respiratory and reproductive viruses affecting cattle and is the first multivalent vaccine marked for infectious bovine rhinotracheitis (IBR) virus and bovine viral diarrhea (BVD) virus.

Key Players Landscape and Outlook

The animal vaccines market is highly dynamic; the market activity reported in recent years includes business agreements and regulatory approvals of products of market players. The market has witnessed many business activities like strategic mergers, acquisitions, and collaborations in recent times.

For instance, in January 2024, Boehringer Ingelheim announced the commercial launch of Vaxxilive Cocci 3, a poultry coccidiosis vaccine previously known as Hatchpak Cocci III. This preventative tool for coccidiosis is a live biological alternative to in-feed anticoccidial drugs. This vaccine stimulates the natural immune response while minimizing tissue damage. VAXXILIVE COCCI 3 is tough on coccidiosis and gentle on birds.

In June 2024, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, announced the launch and availability of the NOBIVAC NXT. The NOBIVAC NXT rabies portfolio is the first-line vaccine that uses frontier RNA-particle technology to prevent rabies caused by cats and dogs. These vaccines made of RNA particles cause both the humoral and cell-mediated responses. The new NOBIVAC NXT vaccines are adjuvant-free and preservative-free, providing better animal safety and protecting dogs and cats against this deadly disease.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Animal Vaccines Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Products
      • 4.2.1.1. Attenuated Live Vaccines
      • 4.2.1.2. Subunit Vaccines
      • 4.2.1.3. DNA Vaccines
      • 4.2.1.4. Recombinant Vaccines
      • 4.2.1.5. Inactivated Vaccines
    • 4.2.2. By Animal Type
      • 4.2.2.1. Livestock Animal Vaccines
      • 4.2.2.2. Companion Animal Vaccines
    • 4.2.3. By Route of Administration
      • 4.2.3.1. Subcutaneous
      • 4.2.3.2. Intramuscular
      • 4.2.3.3. Intranasal
    • 4.2.4. By Distribution
      • 4.2.4.1. Veterinary Clinics
      • 4.2.4.2. Veterinary Hospitals
      • 4.2.4.3. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia-Pacific
      • 4.2.5.4. South America
      • 4.2.5.5. Middle East and Africa
    • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Products
    • 4.3.2. By Animal Type
    • 4.3.3. By Route of Administration
    • 4.3.4. By Distribution
    • 4.3.5. By Region

5. North Animal Vaccines Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Products
      • 5.2.1.1. Attenuated Live Vaccines
      • 5.2.1.2. Subunit Vaccines
      • 5.2.1.3. DNA Vaccines
      • 5.2.1.4. Recombinant Vaccines
      • 5.2.1.5. Inactivated Vaccines
    • 5.2.2. By Animal Type
      • 5.2.2.1. Livestock Animal Vaccines
      • 5.2.2.2. Companion Animal Vaccines
    • 5.2.3. By Route of Administration
      • 5.2.3.1. Subcutaneous
      • 5.2.3.2. Intramuscular
      • 5.2.3.3. Intranasal
    • 5.2.4. By Distribution
      • 5.2.4.1. Veterinary Clinics
      • 5.2.4.2. Veterinary Hospitals
      • 5.2.4.3. Others
    • 5.2.5. By Country Share
      • 5.2.5.1. United States
      • 5.2.5.2. Canada
      • 5.2.5.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Animal Vaccines Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Products
          • 5.3.1.2.1.1. Attenuated Live Vaccines
          • 5.3.1.2.1.2. Subunit Vaccines
          • 5.3.1.2.1.3. DNA Vaccines
          • 5.3.1.2.1.4. Recombinant Vaccines
          • 5.3.1.2.1.5. Inactivated Vaccines
        • 5.3.1.2.2. By Animal Type
          • 5.3.1.2.2.1. Livestock Animal Vaccines
          • 5.3.1.2.2.2. Companion Animal Vaccines
        • 5.3.1.2.3. By Route of Administration
          • 5.3.1.2.3.1. Subcutaneous
          • 5.3.1.2.3.2. Intramuscular
          • 5.3.1.2.3.3. Intranasal
        • 5.3.1.2.4. By Distribution
          • 5.3.1.2.4.1. Veterinary clinics
          • 5.3.1.2.4.2. Veterinary Hospitals
          • 5.3.1.2.4.3. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Animal Vaccines Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Animal Vaccines Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Animal Vaccines Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Animal Vaccines Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Merck & Co, Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 21.3.2. Neogen Corporation
    • 21.3.3. Biogenesis Bago
    • 21.3.4. Vira Vaccine Shaya
    • 21.3.5. Biovac Ltd
    • 21.3.6. Zoetis Services, LLC
    • 21.3.7. Medvet Pharma Pvt, Ltd
    • 21.3.8. Grand Pharma Co, Ltd
    • 21.3.9. LABORATORIOS CALIER, S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 3. Global Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 4. Global Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5. Global Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 6. Global Animal Vaccines Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 8. North America Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 9. North America Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 10. North America Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 11. North America Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 12. North America Animal Vaccines Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 14. United States Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 15. United States Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 16. United States Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 17. United States Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 18. Canada Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 19. Canada Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 20. Canada Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 21. Canada Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22. Canada Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 23. Mexico Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Mexico Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 25. Mexico Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 26. Mexico Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 27. Mexico Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 28. Europe Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Europe Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 30. Europe Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 31. Europe Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Europe Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 33. Europe Animal Vaccines Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 35. Germany Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 36. Germany Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 37. Germany Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Germany Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 39. France Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 40. France Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 41. France Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 42. France Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43. France Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 44. Italy Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Italy Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 46. Italy Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 47. Italy Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 48. Italy Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 49. United Kingdom Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 50. United Kingdom Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 51. United Kingdom Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 52. United Kingdom Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 53. United Kingdom Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 54. Russia Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 55. Russia Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 56. Russia Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 57. Russia Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58. Russia Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 59. Netherlands Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 60. Netherlands Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 61. Netherlands Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 62. Netherlands Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. Netherlands Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 64. Spain Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Spain Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 66. Spain Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 67. Spain Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68. Spain Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 69. Turkey Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Turkey Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 71. Turkey Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 72. Turkey Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73. Turkey Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 74. Poland Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Poland Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 76. Poland Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 77. Poland Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 78. Poland Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 79. South America Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 80. South America Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 81. South America Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 82. South America Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 83. South America Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 84. South America Animal Vaccines Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 86. Brazil Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 87. Brazil Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 88. Brazil Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89. Brazil Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 90. Argentina Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Argentina Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 92. Argentina Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 93. Argentina Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94. Argentina Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 95. Asia-Pacific Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 97. Asia-Pacific Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 98. Asia-Pacific Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. Asia-Pacific Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 100. Asia-Pacific Animal Vaccines Market Share (%), By Country, 2017-2031F
  • Figure 101. India Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. India Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 103. India Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 104. India Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. India Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 106. China Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. China Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 108. China Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 109. China Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 110. China Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 111. Japan Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 112. Japan Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 113. Japan Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 114. Japan Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115. Japan Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 116. Australia Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 117. Australia Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 118. Australia Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 119. Australia Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 120. Australia Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 121. Vietnam Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 122. Vietnam Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 123. Vietnam Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 124. Vietnam Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. Vietnam Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 126. South Korea Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. South Korea Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 128. South Korea Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 129. South Korea Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. South Korea Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 131. Indonesia Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Indonesia Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 133. Indonesia Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 134. Indonesia Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 135. Indonesia Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 136. Philippines Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 137. Philippines Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 138. Philippines Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 139. Philippines Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 140. Philippines Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 141. Middle East & Africa Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 143. Middle East & Africa Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 144. Middle East & Africa Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145. Middle East & Africa Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 146. Middle East & Africa Animal Vaccines Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 149. Saudi Arabia Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 150. Saudi Arabia Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151. Saudi Arabia Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 152. UAE Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 153. UAE Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 154. UAE Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 155. UAE Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 156. UAE Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 157. South Africa Animal Vaccines Market, By Value, In USD Billion, 2017-2031F
  • Figure 158. South Africa Animal Vaccines Market Share (%), By Products, 2017-2031F
  • Figure 159. South Africa Animal Vaccines Market Share (%), By Animal Type, 2017-2031F
  • Figure 160. South Africa Animal Vaccines Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. South Africa Animal Vaccines Market Share (%), By Distribution, 2017-2031F
  • Figure 162. By Products Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Animal Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Distribution Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023